Gilead Sciences, Inc. (GILD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $144.74. The rating moved from Overbought to Oversold on October 1, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$144.74
• Last changeMoved from Overbought to Oversold on October 1, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - General

See all oversold Healthcare stocks →

AI analysis

Gilead Sciences, Inc. (GILD) exhibits a stable cash-flow profile driven by its antiviral franchises and an expanding oncology/cell-therapy footprint, with dividend and buyback activity providing downside cushion. Ongoing payer and policy pressure (Medicare negotiation and shifting MA plan dynamics) plus new single-tablet HIV competition create meaningful near-term pricing risk; late-stage assets and sector defensive flows are the primary upside catalysts to watch. Monitor clinical readouts, regulatory developments, and payer action for the next major directional drivers.

Key factors

• Gilead Sciences, Inc. (GILD) benefits from durable cash flow and a diversified portfolio anchored by HIV therapies and growing oncology/cell therapy assets (Kite acquisition).
• Attractive capital return profile (dividend and buybacks) supports downside protection in a risk-off market.
• Recent regulatory and product approvals across antiviral/HIV space keep the core franchise relevant but invite competitive dynamics.
• Healthcare seen as defensive amid recent risk-off flows, which can support near-term relative price stability.
• Late-stage biologics and specialty biotech investor interest supports M&A/funding optionality for select pipeline assets.

Risks

• Medicare drug-price negotiation (IRA) and heightened policy scrutiny on drug affordability that could compress pricing and margin for high-cost therapies.
• Increased competition in HIV (e.g., new single-tablet entrants such as Bixlenvo) threatening market share and pricing power in core franchises.
• Medicare Advantage benefit expansion and PBM dynamics could increase downward pricing pressure and access constraints.
• Regulatory or clinical setbacks in oncology/cell therapy pipeline (including manufacturing and supply chain risks for complex biologics).
• Macro risk and continued risk-off sentiment could limit upside and depress biotech valuations, reducing M&A appetite and secondary financing windows.

Latest MarketMoodz coverage

• HSBC's Bullish Call on Gilead Leads Five Major Upgrades2026-07-06
• Gilead’s Trodelvy Clears First‑Line TNBC, Market Widens2026-06-25
• Gilead, Merck Halt Trodelvy–Keytruda Lung Trial; Market Impact2026-06-09
• Cramer: Nokia Has Room to Run with ~30% Upside2026-04-15
• Gilead Expands Tempus AI Partnership to Accelerate Oncology Pipeline2026-04-09

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.